Press Releases

Date Title and Summary Additional Formats
Toggle Summary Xencor Reports First Quarter 2017 Financial Results
-- Phase 1 Data from Subcutaneous Administration Trial of XmAb®5871 Support Biweekly Dosing ---- Management to Host Conference Call Today at 4:30 p.m. ET --
View HTML
Toggle Summary Xencor to Host First Quarter 2017 Financial Results Webcast and Conference Call on May 9, 2017
MONROVIA, Calif. , May 2, 2017 /PRNewswire/ --  Xencor, Inc.  (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, announced that it will release first quarter 2017
View HTML
Toggle Summary Xencor to Present at 42nd Annual Deutsche Bank Health Care Conference
MONROVIA, Calif. , April 26, 2017 /PRNewswire/ --  Xencor, Inc.  (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced that Bassil Dahiyat, Ph.D.,
View HTML
Toggle Summary Xencor Appoints Kevin Gorman, Ph.D., to its Board of Directors
MONROVIA, Calif. , April 17, 2017 /PRNewswire/ --  Xencor, Inc.  (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of inflammation and cancer, today announced that Kevin Gorman , Ph.D., chief executive officer of Neurocrine
View HTML
Toggle Summary Xencor to Present at Oppenheimer 27th Annual Healthcare Conference
MONROVIA, Calif. , March 15, 2017 /PRNewswire/ --  Xencor, Inc.  (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced that Bassil Dahiyat , Ph.D.,
View HTML
Toggle Summary Xencor Announces Bruce L.A. Carter, Ph.D., Chairman of the Board of Directors, Will Not Stand for Reelection to Board of Directors at 2017 Annual Meeting of Stockholders
MONROVIA, Calif. , March 6, 2017 /PRNewswire/ -- Xencor , Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of inflammation and cancer, today announced that Bruce L.A. Carter , Ph.D., will not stand for reelection to the
View HTML
Toggle Summary Xencor Presents Preclinical Data on Emerging Bispecific Antibody Candidates at American Association for Cancer Research (AACR) 2017 Annual Meeting
Abstracts available on the AACR Annual Meeting website
View HTML
Toggle Summary Xencor Reports Fourth Quarter and Full Year 2016 Financial Results
-- Reported promising preliminary data from Phase 2 study of XmAb®5871 in IgG4-Related Disease (IgG4-RD) ----Announced strategic collaboration with Novartis for bispecific antibodies---- Robust cash position supports operations beyond 2020 ---- Management to host conference call today at 4:30 p.m. ET --
View HTML
Toggle Summary Xencor to Host Fourth Quarter and Full Year 2016 Financial Results Webcast and Conference Call on February 28, 2017
MONROVIA, Calif. , Feb. 22, 2017 /PRNewswire/ --  Xencor, Inc.  (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, announced that it will release fourth quarter and
View HTML
Toggle Summary IgG4-Related Disease Biomarker Development Update Presented From an Ongoing, Open-label, Phase 2 Study of XmAb®5871 in IgG4-RD at the 3rd International Symposium on IgG4-Related Diseases & Fibrosis
MONROVIA, Calif. , Feb. 18, 2017 /PRNewswire/ -- Xencor , Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced that investigators John H.
View HTML
Xencor © Copyright 2018